Pyrotinib maleate
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2 Mutant Non-small Cell Lung Cancer
Conditions
HER2 Mutant Non-small Cell Lung Cancer
Trial Timeline
Jun 30, 2022 → Dec 31, 2024
NCT ID
NCT05411276About Pyrotinib maleate
Pyrotinib maleate is a pre-clinical stage product being developed by Jiangsu Hengrui Medicine for HER2 Mutant Non-small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05411276. Target conditions include HER2 Mutant Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05411276 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in HER2 Mutant Non-small Cell Lung Cancer